Comprehensive Snapshot of Preimplantation Genetic Testing Market Research Report, Including Regional and Country Analysis in Brief.
Industry: Healthcare
Delivery Timelines: Please Contact Sales
Published Date: June-2025
Format: PPT*, PDF, EXCEL
Number of Pages: 198
ID: PMRREP34757
The global preimplantation genetic testing market is anticipated to reach a value of US$552.7 million in 2025 and reach a value of US$999.2 million at a CAGR of 8.8% by 2032.
The preimplantation genetic testing (PGT) market is experiencing steady growth, driven by the rising prevalence of genetic disorders and increased adoption of in vitro fertilization (IVF) procedures. Technological advancements, such as next-generation sequencing and improved embryo biopsy techniques, have enhanced test accuracy and reliability. Growing awareness among the parents about hereditary diseases and increasing maternal age are also fueling demand. Supportive regulatory frameworks and improved healthcare infrastructure, especially in developed regions, further contribute to market expansion. Additionally, the availability of user-friendly testing kits and automated platforms is streamlining clinical workflows, making PGT more accessible and efficient in fertility treatments.
Key Industry Highlights:
|
Global Market Attribute |
Key Insights |
|
Preimplantation Genetic Testing Market Size (2025E) |
US$ 552.7 Mn |
|
Market Value Forecast (2032F) |
US$ 999.2 Mn |
|
Projected Growth (CAGR 2025 to 2032) |
8.8% |
|
Historical Market Growth (CAGR 2019 to 2024) |
7.3% |
?The expanding use of Assisted Reproductive Technologies (ART) is a significant driver of the growing demand for Preimplantation Genetic Testing (PGT), particularly for aneuploidy screening (PGT-A). As ART procedures become more prevalent, integrating genetic testing allows for the selection of embryos with normal chromosomal structures, enhancing the likelihood of healthy pregnancies and reducing the risk of miscarriage.
In the United States, data from the Centers for Disease Control and Prevention (CDC) indicate a substantial increase in ART utilization. In 2020, U.S. fertility clinics reported 326,468 ART cycles, resulting in 75,023 live-birth deliveries and 79,942 live-born infants. Notably, 62% of these cycles were initiated to transfer at least one embryo, underscoring the widespread application of ART procedures. By 2022, the number of ART cycles performed rose to 435,426, leading to 94,039 live-birth deliveries and 98,289 live-born infants, representing approximately 2.6% of all U.S. births that year.
Concurrently, the application of PGT-A has risen, driven by the increasing number of ART procedures. PGT-A enables the screening of embryos for chromosomal abnormalities before implantation, allowing individuals and couples to avoid passing on genetic conditions associated with aneuploidy. This is particularly pertinent as more individuals with known genetic disorders seek reproductive options to prevent transmission to offspring.
Preimplantation Genetic Testing (PGT), while valuable for detecting chromosomal abnormalities, faces several restraints limiting its broader adoption. One key concern is the potential for embryo damage during the biopsy process, where cells are removed from the trophectoderm layer at the blastocyst stage. Though generally considered safe, studies in Human Reproduction and Fertility and Sterility have linked this procedure to increased pregnancy complications, including a nearly threefold rise in preeclampsia risk and a slightly elevated risk of preterm birth. Diagnostic inaccuracy also undermines trust in PGT. False positives can result in discarding viable embryos.
A 2019 study found that 49.3% of embryos classified as abnormal by PGT-A led to healthy live births upon transfer. Mosaicism further complicates results, with only 42% of retested embryos yielding consistent classifications. Ethical and legal concerns add another layer of restraint. In Australia, Monash IVF settled a $56 million class-action lawsuit involving over 700 patients due to alleged misclassifications from non-invasive PGT-A, highlighting the real-world consequences of diagnostic errors. These risks underscore the need for stringent clinical oversight, enhanced testing accuracy, and thorough patient counseling, which currently hinder widespread PGT market growth.
Technological innovations in genetic analysis are creating major opportunities for enhancing Preimplantation Genetic Testing (PGT) and improving in vitro fertilization (IVF) outcomes. Next-generation sequencing (NGS) enables high-resolution chromosomal analysis, significantly boosting pregnancy and live birth rates, particularly in women of advanced maternal age. In a study of 1,099 couples, NGS-based PGT-A increased the clinical pregnancy rate from 45.6% to 54.4%, and the live birth rate from 30.9% to 52.1%, while reducing miscarriage rates. Artificial intelligence (AI) further transforms PGT by analyzing embryo images to predict viability. Models such as convolutional neural networks (CNNs) and PIMS-AI have achieved high predictive accuracy, with some showing an AUC of 0.90.
Additionally, non-invasive PGT methods using cell-free DNA from spent culture media minimize embryo damage while maintaining diagnostic accuracy. These techniques, especially when integrated with AI, enhance embryo selection, reduce costs, and increase IVF success rates, presenting strong growth opportunities for the PGT market.
Kits hold a prominent position in the preimplantation genetic testing (PGT) market, primarily due to their ability to simplify and standardize the testing workflow. These kits are user-friendly and come with pre-validated reagents and optimized protocols, ensuring consistent and accurate genetic analysis during IVF procedures. By minimizing the risk of human error and reducing reliance on specialized expertise, kits enable broader adoption in fertility clinics. As demand for IVF services grows, clinics are increasingly turning to efficient, scalable solutions, making kits an ideal choice. Their compatibility with automated systems and availability in both advanced and emerging healthcare markets further enhance their adoption, reinforcing their importance within the PGT landscape.
In 2024, the aneuploidy application segment led the preimplantation genetic testing (PGT) market, capturing a substantial 41.0% revenue share. This dominance is attributed to the high prevalence of chromosomal abnormalities, particularly among women of advanced maternal age, and the growing demand to prevent implantation failure and miscarriage.
Aneuploidy testing improves embryo selection by identifying abnormal chromosome numbers, enhancing IVF success rates. It is also the fastest-growing segment, driven by advancements in next-generation sequencing and increasing awareness of genetic screening benefits. Rising acceptance of PGT-A in clinical practice further supports its rapid adoption and sustained market expansion.
?North America holds the largest share in the preimplantation genetic testing (PGT) market, with the U.S. emerging as the leading contributor within the region. This growth is fueled by the widespread adoption of advanced reproductive technologies, increasing awareness of genetic screening, and the presence of leading fertility clinics and PGT providers. The region benefits from significant investment in genetic research and favorable reimbursement policies that enhance access to fertility treatments. A growing number of technologically advanced fertility clinics further supports market expansion. Rising maternal age and a higher prevalence of genetic disorders are also increasing the demand for early genetic screening.
Moreover, strong regulatory support and active collaborations between academic institutions and diagnostic companies foster continuous innovation. These factors collectively position North America as a global leader in both the technological development and clinical application of PGT.
?The European preimplantation genetic testing (PGT) market is witnessing consistent growth, fueled by rising adoption of in vitro fertilization (IVF) and growing awareness of hereditary genetic disorders. Technological advancements in genetic screening methods, along with favorable regulatory frameworks, are enhancing clinical efficiency and test accuracy. The United Kingdom is projected to record the highest compound annual growth rate (CAGR) in the region from 2025 to 2032, driven by increasing fertility treatments and supportive healthcare policies. Moreover, the strong presence of established diagnostic companies and service providers across Europe continues to promote innovation, accessibility, and expansion of the PGT market.
Asia Pacific offers substantial growth potential for the preimplantation genetic testing (PGT) market, fueled by increasing access to fertility care and a growing incidence of genetic disorders. Rising awareness of assisted reproductive technologies and changing social norms around delayed parenthood are driving demand for advanced fertility treatments. Countries such as China, India, and Japan are witnessing rapid urbanization and significant improvements in healthcare infrastructure, creating a strong foundation for market development.
Supportive government policies for infertility treatments and increased investment in genomics research are further accelerating progress. Moreover, the rise of local manufacturers providing cost-effective kits and reagents is improving affordability and access, enabling wider adoption of PGT across various economic and demographic groups.
The preimplantation genetic testing (PGT) market features a dynamic competitive landscape, comprising both established diagnostic companies and emerging biotech firms. Key players are heavily focused on technological advancements, particularly in next-generation sequencing (NGS) and AI-driven embryo analysis, to improve the precision and efficiency of testing. Strategic mergers, acquisitions, and collaborations are prevalent as companies seek to broaden their product offerings and expand their global footprint. There is also increasing competition in the development of user-friendly kits and automated platforms designed to meet the operational needs of fertility clinics.
|
Report Attribute |
Details |
|
Historical Data/Actuals |
2019 - 2024 |
|
Forecast Period |
2025 - 2032 |
|
Market Analysis Units |
Value: US$ Mn, Volume: As applicable |
|
Geographical Coverage |
|
|
Segmental Coverage |
|
|
Competitive Analysis |
|
|
Report Highlights |
|
|
Customization and Pricing |
Available upon request |
By Product
By Technology
By Application
By Distribution Channel
By Region
To know more about delivery timeline for this report Contact Sales
The global market is estimated to increase from US$ 552.7 million in 2025 to US$ 999.2 million in 2032.
Rising IVF procedures, increased genetic disorder awareness, technological advancements, and growing maternal age are key drivers of the PGT market growth.
The market is projected to record a CAGR of 8.8% during the forecast period from 2025 to 2032.
Thermo Fisher Scientific, Inc., COOPER SURGICAL, INC., Illumina, Inc., Abbott, Agilent Technologies, Inc., and Others.
Opportunities lie in AI integration, non-invasive testing, expanding fertility clinics in emerging markets, and improved accessibility through cost-effective testing solutions.
